GENSIGHT BIOLOGICS
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.
GENSIGHT BIOLOGICS
Industry:
Biotechnology Genetics Health Care Medical
Founded:
2012-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.gensight-biologics.com
Total Employee:
11+
Status:
Active
Contact:
+33 1 76 21 72 20
Email Addresses:
[email protected]
Total Funding:
188.93 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt WordPress Google Universal Analytics Apache Wordpress Plugins
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Kodiak Sciences
Kodiak is designing and developing novel therapies for the treatment of retinal disease.
ORIG3N
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Invus
Invus investment in Post-IPO Equity - GenSight Biologics
Arix Bioscience
Arix Bioscience investment in Post-IPO Equity - GenSight Biologics
Sofinnova Partners
Sofinnova Partners investment in Post-IPO Equity - GenSight Biologics
Kreos Capital
Kreos Capital investment in Post-IPO Debt - GenSight Biologics
3sbio
3sbio investment in Post-IPO Debt - GenSight Biologics
Sofinnova Partners
Sofinnova Partners investment in Post-IPO Debt - GenSight Biologics
Sofinnova Partners
Sofinnova Partners investment in Post-IPO Equity - GenSight Biologics
Abingworth
Abingworth investment in Series B - GenSight Biologics
Versant Ventures
Versant Ventures investment in Series B - GenSight Biologics
Perceptive Advisors
Perceptive Advisors investment in Series B - GenSight Biologics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-01 | GenSight Biologics Appoints Sissel Rodahl as Senior Vice-President of Commercial Operations to Lead the Launch of LUMEVOQ® in Europe |
Official Site Inspections
http://www.gensight-biologics.com Semrush global rank: 3.41 M Semrush visits lastest month: 4.59 K
- Host name: coheractio-prod1.alwaysdata.net
- IP address: 185.31.40.193
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "GenSight Biologics"
GenSight Biologics - Crunchbase Company Profile & Funding
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the …See details»
GenSight Biologics — Sofinnova Partners
GenSight Biologics S.A. [SIGHT] is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight …See details»
GenSight Biologics Company Profile - Office Locations ... - Craft
Oct 29, 2024 GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and …See details»
Gensight Biologics SA - Drug pipelines, Patents, Clinical trials
Jul 2, 2025 Explore Gensight Biologics SA with its drug pipeline, therapeutic area, technology platform, 7 clinical trials, 82 news, and 1 literature, Technology Platform:AAV based gene …See details»
Company – GenSight Biologics
Our mission is to turn scientific advances in gene therapy into novel treatments for patients with severe degenerative diseases of the eye and the central nervous system. Our initial focus is …See details»
GenSight Biologics Announces Successful Completion of a Private ...
Jul 1, 2025 GenSight Biologics (the " Company ") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing …See details»
GenSight Biologics - VentureRadar
"GenSight Biologics is a clinical-stage gene therapy company currently focused on discovering, developing and commercializing novel therapies for patients with severe retinal …See details»
GenSight Biologics Announces the Closing of the Company’s c. €4 …
Jul 3, 2025 GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative …See details»
Company Overview – GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight …See details»
GenSight Biologics - Funding, Financials, Valuation & Investors
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.See details»
GenSight Biologics Announces Significant Milestone in New …
Jun 26, 2025 About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal …See details»
Leadership – GenSight Biologics
Our management team is led by our Chief Executive Officer, Laurence Rodriguez, who has over 30 years’ experience in the life sciences industry. She is supported by a management team …See details»
GenSight Biologics Appoints William Monteith to its Board of …
Jun 3, 2024 GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative …See details»
GenSight Biologics Announces Significant Milestone in New …
PARIS, June 26, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and …See details»
Corporate Presentation - GenSight Biologics
Investment Case – Transitioning from R&D to Commercial Organization Late-stage Biotech companySee details»
GenSight Biologics - Contacts, Employees, Board Members
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.See details»
GenSight Biologics Reports Cash Position as of June 30, 2025
Jun 30, 2025 GenSight Biologics (" GenSight Biologics " or the " Company ") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and …See details»
Who we are - GenSight Biologics
We are a gene therapy company seeking to apply pathbreaking science to help patients with severe inherited diseases of the eye and central nervous system.See details»
GenSight Biologics Reports Cash Position as of June 30, 2025
2 days ago Paris, France, July 8, 2025, 8:00 pm CEST – GenSight Biologics (“ GenSight Biologics ” or the “ Company “) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a …See details»
GenSight Biologics Announces Significant Milestone in New …
Jun 26, 2025 “ This outstanding result is a significant milestone in GenSight’s strategy for securing the supply of LUMEVOQ for clinical use and for supporting the planned regulatory …See details»